BactiVac Annual Network Meeting 2019
Following on from the successful 2018 Inaugural Network meeting, our next annual meeting will be held on 20 and 21 March 2019 so please hold the dates in your diary! Find out more about the meeting.
BactiVac receives additional funding from UK Government’s Industrial Strategy Challenge Fund
The BactiVac Network has received an additional £600,000 of funding from The Industrial Strategy Challenge Fund (ISCF). The aim of the ISCF is to bring together the UK world-leading research with business to meet the major industrial and societal challenges of our time. This is part of the government’s £4.7 billion increase in research and development funding over the next 4 years.
BactiVac’s aim to accelerate the development of bacterial vaccines is strongly aligned to the ‘Accelerating innovative healthcare and medicines’ challenge identified as part of the UK government’s investment in the areas of advanced therapies, medicines and vaccines development and manufacturing.
The additional ISCF funding will allow BactiVac to support a larger portfolio of catalyst projects in the Network’s first year of operation, with priority given to projects that particularly:
- demonstrate strong industry engagement and/or are industry led
- focus on the development of a vaccine against bacterial pathogens that are of interest/aligned to UK Health
Outputs from funded catalyst projects will support capacity building and contribute to the ISCF’s target to boost the UK economy, support high-value, highly-skilled manufacturing, and increase productivity. These catalyst pump-priming projects will address key bacterial pathogenic infections that are aligned to UK health priorities.
BactiVac is one of 5 networks that are supported by the Global Challenges Research Fund (GCRF) Networks in Vaccines Research & Development, which is co-funded by the Medical Research Council (MRC) and the Biotechnology and Biological Sciences Research Council (BBSRC).
Dr Martin Broadstock, Programme Manager for Immunology at the MRC, said: “Our goal through the MRC/BBSRC Networks is to accelerate vaccine R&D and the additional ISCF investment will help achieve this by supporting academics and industry partners to work together more closely.”
Professor Cal MacLennan, BactiVac Director welcomed the news of the award, adding that: “this additional government support extends our ability to help advance promising products along the bacterial vaccines pipeline, to the point at which they can be serve their primary purpose of preventing disease and death.”
Bactivac Inaugural Annual Network Meeting
Our Inaugural Annual BactiVac Network Meeting was held on 26 & 27 February 2018 at the University of Birmingham. The meeting focused on sharing our vision, objectives and strategy and provided our members with the opportunity to shape these further. Find out more.
UK International Development Minister visits BactiVac
UK International Development Minister, Alistair Burt, visited the University of Birmingham on 22 February 2018 to find outmore about BactiVac and what the Network is aiming to achieve. Professor Adam Cunningham, co-Director of the BactiVac Network, spoke to Alistair Burt about the importance of working in partnership with LMICs and across the academia/industry divide to accelerate the development of bacterial vaccines to prevent disease and save lives. Find out more about the visit here.
Listen to what Alistair Burt had to say about the importance of BactiVac.
Launch of the Vaccine Development Toolkit
The MRC, BBSRC and Department of Health have launched a vaccine development process map to show the key stages in vaccine development. The map was developed by the UK Vaccine R&D Network to facilitate understanding of the key stages in vaccine development and importantly, where bottlenecks could potentially delay progress.
The UK Vaccine R&D Network have also produced a summary of key points to guide decision making in the context of an emergency response to an epidemic or pandemic and carried out case studies to highlight where bottlenecks in vaccine development occur in response to an outbreak. The toolkit also includes details case studies where three candidate vaccines were evaluated against the process map to verify if the bottlenecks identified were accurate.
BactiVac network launched
Researchers from the University of Birmingham have established a global bacterial vaccinology network that brings key individuals and organisations together to facilitate end-to-end bacterial vaccine development for low and middle income countries (LMICs).